Arda Therapeutics is a biotechnology company specializing in targeted cell depletion therapies aimed at treating chronic diseases by eliminating pathogenic cells that drive these conditions.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
The approach is to utilize a single-cell-based discovery engine to identify specific pathogenic cells and their surface markers with high precision. This enables the development of targeted biologics that selectively eliminate harmful cells while preserving healthy tissue, potentially leading to greater efficacy and fewer side effects compared to conventional treatments.
Leveraging the insights gained from their discovery engine, Arda Therapeutics aims to develop targeted biologics designed to selectively eliminate harmful cells while preserving healthy tissue. One of their primary therapeutic modalities includes Antibody-Drug Conjugates (ADCs), a technology that has seen significant advancements in recent years. By adapting ADC technology, which is traditionally used in oncology, to address fibrotic diseases, the company aims to capitalize on this momentum and apply it to non-oncology indications.
The company’s platform has broad applicability across a range of diseases, including fibrotic conditions such as pulmonary fibrosis, as well as autoimmune and metabolic disorders. While specific details about their development pipeline are not publicly disclosed, this targeted strategy can hopefully enable Arda Therapeutics to identify potential anti-aging treatments that could slow down or reverse aspects of the aging process by removing detrimental cells from the body.
The Company
Arda Therapeutics was founded in 2021, and is headquartered in San Carlos, California. The company was founded by Adam Freund, who is the CEO, and co-founded by Remi-Martin Laberge, who is the CTO.
Arda Therapeutics has successfully secured funding to advance its research and development efforts. In October 2024, the company completed a Series A financing round, raising $43 million. This round was led by Andreessen Horowitz (a16z Bio + Health), with participation from investors including Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV, Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels, and ExitFund.
While specific strategic partnerships have not been publicly detailed, the involvement of prominent investors such as Eli Lilly and Company suggests potential collaborative opportunities in the future. Additionally, the appointment of Scott Turner as Chief Scientific Officer, who brings extensive experience in fibrosis drug discovery, indicates a strengthening of the company’s scientific leadership.
Read about more anti-aging companies on this website through this link.
